Monsenso signs contract with the Norwegian University of Science & Technology

Monsenso signs contract with the Norwegian University of Science & Technology

Monsenso has signed a contract with the Norwegian University of Science & Technology to use Monsenso’s digital health solution to collect sensor data in a research project aiming at improving relapse prevention with substance use disorders.

The research study aims to improve the prediction of relapse using mobile sensing to identify a digital phenotype approach to relapse prevention. The research project is led by Anders Lauvsnes, Department of Mental Health, Faculty of Medicine and Health Sciences, at the Norwegian University of Science & Technology and covers up to 100 research participants with substance use disorders.

Mobile sensing, the use of passive data generated by personal electronic devices such as smartphones and wearables to measure human functioning, has generated considerable research interest over the past years. Particularly in the field of mental health, where the collection of continuous and objective data can lead to clinically useful biomarkers to support the prevention, early intervention, and treatment of a variety of conditions, including addiction.

“Addiction and substance use disorders are major health challenges worldwide, and relapse is a core component of addictive disorders. The dynamics surrounding relapse, and particularly the immediate period leading up to it, are only partially understood, due in large part to the difficulty of collecting reliable and sufficient data from this narrow period,” says Anders Lauvsnes. “Mobile sensing offers the opportunity to identify predictive patterns of relapse by accurately mapping behaviour. Together with data on symptoms worsening, it can help us identify a digital phenotype for relapse prevention”.

The Monsenso digital solution will be used to remotely monitor study participants, collecting sensor data from mobile phones along with sensor data from wearables (Whitings). After completion of the data collection, the data will be analysed along with neurocognitive measures using machine learning to predict imminent relapse to substance use and describe individual and temporal variability in risk.

“We are very excited to contribute to this project of creating a digital phenotype to help reduce relapse,” said Thomas Lethenborg, CEO of Monsenso. “Mobile sensing does indeed offer a data-driven method to improve condition monitoring for actionable outcomes, such as early signs of relapse, thereby ensuring the right individuals receive the right treatment at the right time”.

About Monsenso digital health solution:
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Monsenso signs two contracts with the Psychiatric Research Unit, Region West Zealand.

Monsenso signs two contracts with the Psychiatric Research Unit, Region West Zealand.

Monsenso signs two contracts with Research Unit for Psychotherapy and Psychopathology, Psychiatry West, Slagelse, Region Zealand Mental Health Services, who will use Monsenso’s digital health solution to remotely monitor patients with depression and schizotypal mental illness, respectively.

The first project, Development of an Intervention for Persistent Not on Track: DIP NOT, led by Jasmin Rejaye Gryesten, aims to identify non-responders to depression treatment, with the ultimate goal of increasing the number of remitted patients after CBT in the Danish MHS by developing a set of new person-centered add-on interventions to group CBT, to be used in case of observed lack of progress or deterioration.

The second project Phenomenologically informed PsychoTherapy for patients with Schizotypal Personality Disorder (PPT -SPD), is led by Kåre Donskov Nielsen and aims to develop and test new forms of phenomenological therapy that can help people with schizotypal mental illness.

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Monsenso signs a new contract with Empano

Monsenso signs a new contract with Empano

Monsenso expands collaboration with Empano, a private provider of psychology and psychiatry services, signing a new contract to help citizens with stress return to work in the municipality of Slagelse.

Monsenso and Empano partnered up last year to help unemployed people get back to work faster. Together, Monsenso and Empano offer a solution for Danish municipalities to help unemployed people suffering from stress and depression return to work.
Following the successful implementation in the municipality of Guldborgssund, the services are now offered to more municipalities, starting in the municipality of Slagelse, Denmark.

Empano offers individual courses and group sessions to the employment sector in the municipalities and uses Monsenso’s digital health solution to collect self-reported data from service users to validate and demonstrate the program’s effectiveness.

The courses have a duration of 6-8 weeks each, after which new citizens are enrolled.

It is a preventative course that teaches strategies to reduce stress and promote mental health. Citizens are introduced to techniques that enable them to better cope with symptoms and challenges in everyday life and the job market, based on cognitive therapy, metacognitive therapy, and mindfulness.

“We are excited to expand our collaboration with Empano to help more people get back to work faster,” says CEO Thomas Lethenborg. “Mental health and unemployment are closely linked. While unemployment can cause stress which may have other negative consequences on people’s mental health, including depression, anxiety and lower self-esteem, a good mental health has shown to have a positive impact on employability, finding a job and staying in that job.”

Monsenso signs a contract with the Elite Sports Academy Aarhus (ESAA)

Monsenso signs a contract with the Elite Sports Academy Aarhus (ESAA)

Monsenso signs a contract with the Elite Sports Academy Aarhus (ESAA). The Monsenso digital health solution will be used to promote mental wellbeing among ESAA’s students.

Strong mental health is a prerequisite for top athletes to perform at their best. Yet, top athletes are more vulnerable to psychological distress due to the top performance culture. In response, many clubs have over the recent years taken initiatives to promote mental health among their elite athletes and today sports psychology is as much about mental health, as it is about athletic performance.

ESAA, an Elite Sports Academy located in Aarhus (Denmark), is no exception. With mental health as part of the academy’s core values (Mind, Body, Culture, Team), ESAA seeks to provide their young athletes with self-insight and tools to learn how to master the mental aspects of being an elite athlete.

From August 2021, 75 young elite athletes will be offered the Monsenso mhealth app as part of ESAA’s talent program to track their mental wellbeing daily, while giving them access to “Tools” and “Challenges” to boost their mental health and wellbeing. ‘Tools’ provides the young athletes with coping strategies and ‘Challenges’ helps to learn new skills, like how to gain insight into their emotions, how to develop a positive mindset or improve their confidence.

At the same time, the daily tracking offers ESAA the opportunity to identify and act proactively upon signs and symptoms of mental distress, and hereby to provide preventive support to their young athletes.

 “We are pleased to collaborate with ESAA in this project,” says Thomas Lethenborg, CEO of Monsenso. “The importance of mental health in elite sport, in particular among young athletes, can not be underestimated and we are happy that the Monsenso solution can contribute to that. 

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

 

 

 

Monsenso announces new chairman of the Board

Monsenso announces new chairman of the Board

Copenhagen, (April 14, 2021): Monsenso, a leading provider of digital mental health solutions, today announced the appointment of Maria Hjorth as Chairman of the Board, as replacement of Jukka Pekka Pertola, who had decided to resign to reduce his number of board seats. 

The company’s Annual General Meeting was held today, in which Maria Hjorth was elected to join the board. Immediately after the Annual General Meeting, the Board of Directors held its constituent meeting and elected Maria Hjorth as Chairman and re-elected Jakob Eyvind Bardram as Deputy Chairman.

The appointment of Maria Hjorth as chairman follows changes in January where Peter Høngaard Andensen and Jacob Hahn Michelsen were elected to the Board with the aim to further strengthen the competences and the diversity of the board.

 “Maria brings extensive experience and accomplishments from the financial sector, lately from a position as CEO at VP Securities A/S, in addition to her board experience from Trifork, May Invest Holding A/S and Asetek” says CEO Thomas Lethenborg. “Her experiences from top management, financial businesses, investor relations and M&A is a great supplement to the rest of the board”. 

The Board and the management of Monsenso would like to thank Jukka Pertola for his great efforts in supporting the management, the company in general and particularly the listing on Nasdaq First North Growth Market in 2020.

“It has been a great pleasure to have served as Chairman of the Monsenso Board of Directors,” said Jukka Pertola. “I am very proud of our accomplishments over the past years, and I am confident that with Maria’s leadership, and the changes made in January, Monsenso will continue to grow and expand it’s positive impact in driving better mental health for more people at lower cost.”

The Board of Directors now consists of Maria Hjorth (Chairman), Jakob E. Bardram (Deputy Chairman), Jeppe Ø. Øvlesen, Peter Høngaard Andersen and Jacob Hahn Michelsen. 

To read the Danish version, click here.

For additional information contact:

Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso